1. Sanofi pulls teplizumab from FDA fast-track program after political appointee Høeg allegedly blocked staff approval
Sanofi has requested the removal of its type 1 diabetes drug teplizumab from Commissioner Marty Makary's expedited review initiative, according to sources familiar with the matter. The request follows an internal dispute at the Food and Drug Administration in which acting Center for Drug Evaluation and Research directo...